Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAM Brookfield Asset Management	$63.03 -0.2%	$56.87	$38.18 ▼ $63.53	$103.47B	1.43	2.83 million shs	1.26 million shs
GLW Corning	$55.37 -0.6%	$51.45	$37.18 ▼ $56.25	$47.72B	1.11	3.97 million shs	4.72 million shs
PFE Pfizer	$24.79 -2.2%	$24.30	$20.92 ▼ $31.54	$144.12B	0.58	38.21 million shs	35.63 million shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	86 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAM Brookfield Asset Management	+1.21%	+2.68%	+13.49%	+19.28%	+53.69%
GLW Corning	-0.10%	+2.77%	+8.26%	+26.11%	+26.77%
PFE Pfizer	+0.19%	+3.17%	+4.39%	+10.56%	-15.38%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BAM Brookfield Asset Management	4.4119 of 5 stars	2.3	4.0	0.8	2.8	3.7	2.5	1.9
GLW Corning	3.4137 of 5 stars	2.4	3.0	1.7	0.0	3.3	2.5	1.9
PFE Pfizer	4.9819 of 5 stars	3.2	3.0	4.2	4.5	4.0	1.7	3.1
SGEN Seagen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAM Brookfield Asset Management	2.53	Moderate Buy	$59.64	-5.38% Downside
GLW Corning	2.85	Moderate Buy	$57.73	4.27% Upside
PFE Pfizer	2.45	Hold	$28.55	15.19% Upside
SGEN Seagen	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BAM, PFE, SGEN, and GLW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/25/2025	GLW Corning	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$62.00 ➝ $65.00
7/17/2025	GLW Corning	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$52.00 ➝ $62.00
7/15/2025	GLW Corning	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$52.00 ➝ $59.00
7/11/2025	BAM Brookfield Asset Management	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$55.00 ➝ $57.00
7/11/2025	GLW Corning	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $60.00
7/9/2025	GLW Corning	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$54.00 ➝ $57.00
7/8/2025	GLW Corning	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$44.00 ➝ $50.00
7/8/2025	GLW Corning	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/30/2025	BAM Brookfield Asset Management	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$60.00
6/18/2025	BAM Brookfield Asset Management	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$68.00 ➝ $72.00
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAM Brookfield Asset Management	$3.98B	25.93	$5.61 per share	11.24	$7.80 per share	8.08
GLW Corning	$13.12B	3.61	$3.54 per share	15.65	$12.93 per share	4.28
PFE Pfizer	$63.63B	2.21	$4.27 per share	5.81	$15.62 per share	1.59
SGEN Seagen	$2.30B	18.66	N/A	N/A	$15.10 per share	15.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAM Brookfield Asset Management	$541M	$1.41	44.70	31.68	2.45	55.26%	52.70%	35.46%	8/6/2025 (Estimated)
GLW Corning	$506M	$0.52	106.47	20.28	1.50	3.34%	16.47%	6.64%	7/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.96	8.18	0.92	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
SGEN Seagen	-$610.31M	-$4.01	N/A	N/A	N/A	-32.61%	-28.06%	-20.92%	N/A

Latest BAM, PFE, SGEN, and GLW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	BAM Brookfield Asset Management	$0.41	N/A	N/A	N/A	$1.29 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
7/29/2025	Q2 2025	GLW Corning	$0.57	N/A	N/A	N/A	$3.84 billion	N/A
5/6/2025	Q1 2025	BAM Brookfield Asset Management	$0.40	$0.40	N/A	$0.36	$1.29 billion	$1.04 billion
4/29/2025	Q1 2025	GLW Corning	$0.51	$0.54	+$0.03	$0.18	$3.63 billion	$3.68 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAM Brookfield Asset Management	$1.75	2.78%	N/A	124.11%	2 Years
GLW Corning	$1.12	2.02%	N/A	215.38%	N/A
PFE Pfizer	$1.72	6.94%	N/A	124.64%	16 Years
SGEN Seagen	N/A	N/A	N/A	N/A	N/A

Latest BAM, PFE, SGEN, and GLW Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/26/2025	GLW Corning	quarterly	$0.28	2.2%	8/29/2025	8/29/2025	9/29/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
5/6/2025	BAM Brookfield Asset Management	quarterly	$0.4375	3.25%	5/30/2025	5/30/2025	6/30/2025
5/2/2025	GLW Corning	quarterly	$0.28	2.4%	5/30/2025	5/30/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAM Brookfield Asset Management	0.07	1.31	1.31
GLW Corning	0.62	1.69	1.05
PFE Pfizer	0.64	1.26	0.96
SGEN Seagen	N/A	2.67	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAM Brookfield Asset Management	68.41%
GLW Corning	69.80%
PFE Pfizer	68.36%
SGEN Seagen	84.26%

Insider Ownership

Company	Insider Ownership
BAM Brookfield Asset Management	11.00%
GLW Corning	0.40%
PFE Pfizer	0.06%
SGEN Seagen	25.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAM Brookfield Asset Management	250,000	1.64 billion	1.46 billion	Optionable
GLW Corning	56,300	856.47 million	853.05 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
SGEN Seagen	3,256	187.70 million	139.08 million	Optionable

BAM, PFE, SGEN, and GLW Headlines

Recent News About These Companies

Trial win sets up new use for Astellas, Seagen's Padcev in bladder cancer

March 15, 2025 | pharmaphorum.comP

Merck in "advanced talks" for $40bn Seagen bid; report

March 7, 2025 | pharmaphorum.comP

Seagen posts breast cancer win ahead of Pfizer takeover

February 23, 2025 | pharmaphorum.comP

Is Merck planning a $30bn-plus move for Seagen?

December 6, 2024 | pharmaphorum.comP

Pfizer raises guidance as COVID franchise drives Q3 beat

October 30, 2024 | seekingalpha.com

Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed

October 30, 2024 | seekingalpha.com

Franklin Biotechnology Discovery C

October 5, 2024 | morningstar.comM

Seagen wins Enhertu patent dispute with Daiichi Sankyo

July 19, 2024 | pharmaphorum.comP

Pfizer: Turning The Corner (Rating Upgrade)

May 27, 2024 | seekingalpha.com

Two Brothers, a Big Biotech Bet and an $8 Billion Payout

April 13, 2024 | wsj.com

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

April 2, 2024 | pharmaphorum.comP

Ron Baron Portfolio Magic: Building Your Financial Future

March 20, 2024 | msn.com

Bailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving markets

March 13, 2024 | msn.com

Pfizer shutting down Seagen's $350M construction project in Everett

March 1, 2024 | bizjournals.com

Neuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk Says

February 24, 2024 | finance.yahoo.com

MRNA Feb 2024 64.000 put

February 23, 2024 | finance.yahoo.com

MRNA Feb 2024 77.000 call

February 23, 2024 | finance.yahoo.com

Pfizer adds bull at Guggenheim on ex-COVID prospects

February 23, 2024 | msn.com

MRNA Feb 2024 67.000 put

February 22, 2024 | finance.yahoo.com

Pfizer touts cancer efforts in first Super Bowl commercial

February 12, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

BAM, PFE, SGEN, and GLW Company Descriptions

Brookfield Asset Management NYSE:BAM

$63.03 -0.16 (-0.25%)

Closing price 03:59 PM Eastern

Extended Trading

$63.04 +0.01 (+0.01%)

As of 07:58 PM Eastern

Brookfield Asset Management Ltd. is a real estate investment firm specializing in alternative asset management services. Its renewable power and transition business includes the operates in the hydroelectric, wind, solar, distributed generation, and sustainable solution sector. The company's infrastructure business engages in the utilities, transport, midstream, and data infrastructure sectors. In addition, its private equity business offers industrial, infrastructure, and business services sectors; and real estate business, which includes housing, logistics, hospitality, science and innovation, office, and retail sectors. Further, it provides credit business; and insurance solution in the reinsurance, annuities, operating platform, and investment solutions sectors. Brookfield Asset Management Ltd. was incorporated in 2022 and is headquartered in Toronto, Canada.

Corning NYSE:GLW

$55.36 -0.36 (-0.64%)

Closing price 03:59 PM Eastern

Extended Trading

$55.24 -0.13 (-0.23%)

As of 07:58 PM Eastern

Corning Incorporated engages in the display technologies, optical communications, environmental technologies, specialty materials, and life sciences businesses in the United States and internationally. The company's Display Technologies segment offers glass substrates for flat panel displays, including liquid crystal displays and organic light-emitting diodes that are used in televisions, notebook computers, desktop monitors, tablets, and handheld devices. Its Optical Communications segment provides optical fibers and cables; and hardware and equipment products, such as cable assemblies, fiber optic hardware and connectors, optical components and couplers, closures, network interface devices, and other accessories for the telecommunications industry, businesses, governments, and individuals. The company's Specialty Materials segment manufactures products that offer material formulations for glass, glass ceramics, crystals, precision metrology instruments, and software, as well as glass wafers and substrates, tinted sunglasses, and radiation shielding products for various markets comprising mobile consumer electronics, semiconductor equipment optics and consumables, aerospace and defense optics, radiation shielding products, sunglasses, and telecommunications components. Its Environmental Technologies segment provides ceramic substrates and filter products for emissions control in mobile, gasoline, and diesel applications. The company's Life Sciences segment offers laboratory products, including consumables, such as plastic vessels, liquid handling plastics, specialty surfaces, cell culture media, and serum, as well as general labware, and glassware and equipment under the Corning, Pyrex, Falcon, and Axygen brands. The company was formerly known as Corning Glass Works and changed its name to Corning Incorporated in April 1989. Corning Incorporated was founded in 1851 and is headquartered in Corning, New York.

Pfizer NYSE:PFE

$24.78 -0.57 (-2.23%)

Closing price 03:59 PM Eastern

Extended Trading

$24.80 +0.02 (+0.08%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time